<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320650">
  <stage>Registered</stage>
  <submitdate>30/09/2009</submitdate>
  <approvaldate>30/09/2009</approvaldate>
  <actrnumber>ACTRN12609000848202</actrnumber>
  <trial_identification>
    <studytitle>A clinical study in healthy volunteers to determine whether orally consumed tocopheryl phosphates are incorporated into oil produced/secreted by the skin.</studytitle>
    <scientifictitle>A clinical study in healthy volunteers to determine whether orally consumed tocopheryl phosphates are incorporated into secreted sebum</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>POH022-09</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Tocopheryl phosphates and secreted sebum.</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Normal skin development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Mixed tocopheryl phosphates (TPM) capsules at approx. 400 International Units (IU) (~316 mg) to be taken once a day  (after breakfast, between 7 am and 9 am), for 28 days.</interventions>
    <comparator>Alpha-tocopheryl acetate capsules at approx. 400 IU (~316 mg) to be taken once a day (after breakfast, between 7 am and 9 am), for 28 days.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if orally consumed mixed tocopheryl phosphates increase plasma, skin and sebum tocopheryl phosphate and di-tocopheryl phosphate concentrations.</outcome>
      <timepoint>Blood samples for plasma PK analysis will be collected on Days 0 (baseline), 1, 3, 7, 14, 21 and 28.

Sebum samples will be collected from the forehead (by use of Sebutape strip) on Days 0 (baseline), 1, 3, 7, 14, 21 and 28.

Skin samples will be collected by tape stripping (Food &amp; Drug Administration (FDA) approved) of the volar forearm on Days 0 (baseline), 1, 3, 7, 14, 21 and 28, and from the forehead on Day 28.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine if mixed tocopheryl phosphate tablets increase alpha-tocopherol content in the plasma, skin and sebum.</outcome>
      <timepoint>Blood samples for plasma PK analysis will be collected on Days 0 (baseline), 1, 3, 7, 14, 21 and 28.

Sebum samples will be collected from the forehead (by use of Sebutape strip) on Days 0 (baseline), 1, 3, 7, 14, 21 and 28.

Skin samples will be collected by tape stripping (FDA approved) of the volar forearm on Days 0 (baseline), 1, 3, 7, 14, 21 and 28, and from the forehead on Day 28.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Provision of written informed consent.
- "Healthy" male or female.
- At least 18 years old.
- Fitzpatrick skin types II or III.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>- Pregnant or breastfeeding.
- History of dermatological disorders.
- Current medical problems or systemic medication.
- Oral or topical anti-oxidant supplementation within 14 days of baseline.
- Smokers.
- Exposure to intense solar or artificial UV/ tanning salons in the 3 months prior to baseline.
- Unable or unwilling to use Vitamin E free skin care products for the duration of the trial.
- Taking warfarin or blood thinning medications.
- Dependent on iron supplements.
- Diabetes, hyperthyroidism, or heart disease.
- Unwilling or unable to avoid ultraviolet (UV) exposure for the duration of the trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Educational / counselling / training</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be randomly allocated to a study treatment (using a manual block system of allocation to treatments).  

The study is open label so all participants will be aware of which arm they are on.
</concealment>
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate>26/10/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>3/08/2012</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Phosphagenics Limited</primarysponsorname>
    <primarysponsoraddress>11 Duerdin Street
Clayton VIC 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Phosphagenics Limited</fundingname>
      <fundingaddress>11 Duerdin Street
Clayton VIC 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Alpha-tocopherol plays an important role in preserving skin barrier function; it is concentrated in sebum and secreted to the skin in high concentrations.  It is not known whether supplemented tocopheryl phosphates, which have been shown to play a protective role in prevention of UV damage, follow a similar metabolic pathway to the skin surface as alpha-tocopherol.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health Human Research Ethics Committee</ethicname>
      <ethicaddress>246 Clayton Road
Clayton, Victoria 3168</ethicaddress>
      <ethicapprovaldate>30/09/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>11/09/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Miss</title>
      <name>Yelda Ogru</name>
      <address>Phosphagenics Ltd 
11 Duerdin St
Clayton, 3168
VICTORIA</address>
      <phone>+61 3 9565 1156</phone>
      <fax>+61 3 9565 1151</fax>
      <email>yogru@phosphagenics.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Miss</title>
      <name>Yelda Ogru</name>
      <address>Phosphagenics Ltd 
11 Duerdin St
Clayton, 3168
VICTORIA</address>
      <phone>+61 3 9565 1156</phone>
      <fax>+61 3 9565 1151</fax>
      <email>yogru@phosphagenics.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Roksan Libinaki</name>
      <address>Phosphagenics Ltd 
11 Duerdin St
Clayton, 3168
VICTORIA</address>
      <phone>+61 3 9565 1119</phone>
      <fax />
      <email>rlibinaki@phosphagenics.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>